PERSEUS: Daratumumab plus VRd in Newly Diagnosed Multiple Myeloma Patients
Multiples Myelom: Erstlinientherapie im Transplant-Setting | Im Fokus
Perseus Study - EMN 17 - Multiple Myeloma Clinical Trials
EMN17 - European Myeloma Network
How I treat relapsed multiple myeloma - ScienceDirect
GRIFFIN Update: Dara-R Maintenance - Slideset Download - Hematology 2021 | CCO
Treatment approach for transplant ineligible patients. Dara‐VRd,... | Download Scientific Diagram
Multiple Myeloma Hub on X: "CONGRESS | #IMW2019 | Peter Voorhees, @levinecancer, presents the GRIFFIN study of dara-VRd in transplant eligible NDMM. Study results suggest Dara-RVd may be a new SOC for
ASH23: Perseus Trial: DARA + VRd vs. Vrd Alone in ASCT-Eligible Patients | Pieter Sonneveld, MD, PhD - YouTube
Cancers | Free Full-Text | Recent Advances in the Treatment of Patients with Multiple Myeloma
Perseus Study - EMN 17 - Multiple Myeloma Clinical Trials
Multiple myeloma with high-risk cytogenetics and its treatment approach | International Journal of Hematology
Dara-(C)VRd pre- and post-ASCT for ultra-high risk MM and primary plasma cell leukemia
PERSEUS: Primary efficacy and safety results
Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma
Phase 3 Perseus Trial in Patients Eligible for ASCT | Int'l Myeloma Fn
Review of Primary Outcomes from the PERSEUS Trial of Subcutaneous DARA+VRd in Transplant-Eligible Newly Diagnosed Multiple Myeloma
UK OPTIMUM/MUKnine: Dara-VRd in Ultra-High‒Risk NDMM - Slideset Download - | CCO
Pharmaceuticals | Free Full-Text | The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
Cancers | Free Full-Text | Multiple Myeloma: An Overview of the Current and Novel Therapeutic Approaches in 2020
Multiple myeloma current treatment algorithms | Blood Cancer Journal
